Of the tracked stories, 1 of 2 also mention Abbott Laboratories, the most common co-covered peer. Source depth averages 2.5 original sources per story, versus 3 across the same-window beat baseline. At 6, the average consequence score sits below the same-window beat average of 6.9.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Exact Sciences
Of the tracked stories, 1 of 2 also mention Abbott Laboratories, the most common co-covered peer. Source depth averages 2.5 original sources per story, versus 3 across the same-window beat baseline. At 6, the average consequence score sits below the same-window beat average of 6.9. acquisition accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Exact Sciences appears in 2 tracked Biotech stories published from July 17, 2026 through July 22, 2026.
Stories tracked
2
Sources per story
2.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Exact Sciences. Shared-story counts are live from our verified record — not editorial picks.
Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.